Phenylpropanoic acid derivatives bearing a benzothiazole ring as PPARδ-selective agonists

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 15, 2007, Pages 4351-4357

  Fujieda, Hiroki ^a   Usui, Shinya ^a   Suzuki, Takayoshi ^a   Nakagawa, Hidehiko ^a   Ogura, Michitaka ^b   Makishima, Makoto ^b   Miyata, Naoki ^a  

^a NAGOYA CITY UNIVERSITY   (Japan)

^b NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Agonist; Drug design; Metabolic syndrome; Nuclear receptor; PPAR

Indexed keywords

[2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; BENZOTHIAZOLE; ETHYLENE GLYCOL; GW 2433; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PHENYLPROPANOIC ACID DERIVATIVE; PIRINIXIC ACID; PROPIONIC ACID DERIVATIVE; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ARTICLE; DRUG DESIGN; DRUG SYNTHESIS; IN VITRO STUDY; MITSUNOBU REACTION; MOLECULAR MODEL; SUSTAINED RELEASE PREPARATION;

BENZOTHIAZOLES; HUMANS; MODELS, MOLECULAR; PHENYLPROPIONATES; PPAR DELTA; PYRIMIDINES;

EID: 34347380861     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.05.017     Document Type: Article

References (30)

1. Willson T.M., Brown P.J., Sternbach D.D., and Henke B.R. J. Med. Chem. 43 (2000) 527
2. Staels B., Dallongeville J., Auwerx J., Schoonjans E., Leitersdorf E., and Fruchart J.-C. Circulation 98 (1998) 2088
3. Way J.M., Harrington W.W., Brown K.K., Gottschalk W.K., Sundseth S.S., Mansfield T.A., Ramachandran R.K., Willson T.M., and Kliewer S.A. Endocrinology 142 (2001) 1269
4. Forman B.M., Chen J., and Evans R.M. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 4312
5. Cantello B.C.C., Cawthorone M.A., Cottam G.P., Duff P.T., Haigh D., Hindley R.M., Lister C.A., Smith S.A., and Thurlby P.L. J. Med. Chem. 37 (1994) 3977
6. Momose Y., Meguro K., Ikeda H., Hatanaka C., Oi S., and Sohda T. Chem. Pharm. Bull. 39 (1991) 1440
7. Wang Y.-X., Lee C.-H., Tiep S., Yu R.T., Ham J., Kang H., and Evans R.M. Cell 113 (2003) 159
8. Wang Y.-X., Zhang C.-L., Yu R.T., Cho H.K., Nelson M.C., Bayuga-Ocampo C.R., Ham J., Kang H., and Evans R.M. PloS. Biol. 2 (2004) 1532
9. Leibowitz M.D., Fievet C., Hennuyer N., Peinado-Onsurbe J., Duez H., Berger J., Cullinan C.A., Sparrow C.P., Baffic J., Berger G.D., Santini C., Marquis R.W., Tolman R.L., Smith R.G., Moller D.E., and Auwerx J. FEBS Lett. 473 (2000) 333
10. Tanaka T., Yamamoto J., Iwasaki S., Asaba H., Hamura H., Ikeda Y., Watanabe M., Magoori K., Ioka R.X., Tachibana K., Watanabe Y., Uchiyama Y., Sumi K., Iguchi H., Ito S., Doi T., Hamakubo T., Naito M., Auwerx J., Yanagisawa M., Kodama T., and Sakai J. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 15924
11. Graham T.L., Mookherjee C., Suckling K.E., Palmer C.N.A., and Patel L. Atherosclerosis 181 (2005) 29
12. Lee C.-H., Chawla A., Urbiztondo N., Liao D., Boisvert W.A., and Evans R.M. Science 302 (2003) 453
13. Although compound 1 showed weak transactivation activity for PPARγ (Fig. 2), it displayed high affinity to PPARγ in a binding assay (Ref. 14,15).
14. Usui S., Suzuki T., Hattori Y., Etoh K., Fujieda H., Nishizuka M., Imagawa M., Nakagawa H., Kohda K., and Miyata N. Bioorg. Med. Chem. Lett. 15 (2005) 1547
15. Usui S., Fujieda H., Suzuki T., Yoshida N., Nakagawa H., and Miyata N. Bioorg. Med. Chem. Lett. 16 (2006) 3249
16. Fukuyama T., Jow C.-K., and Cheung M. Tetrahedron Lett. 36 (1995) 6373
17. Fukuyama T., Cheung M., Jow C.-K., Hidai Y., and Kan T. Tetrahedron Lett. 38 (1997) 5831
18. Mitsunobu O. Synthesis (1981) 1
19. Wagaw S., and Buchwald S.L. J. Org. Chem. 61 (1996) 7240
20. Maryanoff B.E., and Reitz A.B. Chem. Rev. 89 (1989) 863
21. Li T., Fujita Y., Tsuda Y., Miyazaki A., Ambo A., Sasaki Y., Jinsmaa Y., Bryant S.D., Lazarus L.H., and Okada Y. J. Med. Chem. 48 (2005) 586
22. Beletskaya I.P., and Cheprakov A.V. Chem. Rev. 100 (2000) 3009
23. Fukuen S., Iwaki M., Yasui A., Makishima M., Matsuda M., and Shimomura I. J. Biol. Chem. 280 (2005) 23653
24. TM MX multilabel counter (Perkin-Elmer, Boston, MA, U.S.A.). DNA cotransfection experiments included 58 ng of reporter plasmid, 12 ng of CMX-β-galactosidase, and 18 ng of each receptor expression plasmid per well in a 96-well plate. Luciferase data were normalized to an internal β-galactosidase control and reported values are means of triplicate assays.
25. Xu H.E., Lambert M.H., Montana V.G., Parks D.J., Blanchard S.G., Brown P.J., Sternbach D.D., Lehmann J.M., Wisely G.B., Willson T.M., Kliewer S.A., and Milburn M.V. Mol. Cell 3 (1999) 397
26. Epple R., Azimioara M., Russo R., Bursulaya B., Tian S.-S., Gerken A., and Iskandar M. Bioorg. Med. Chem. Lett. 16 (2006) 2969
27. Weigand S., Bischoff H., Dittrich-Wengenroth E., Heckroth H., Lang D., Vaupel A., and Woltering M. Bioorg. Med. Chem. Lett. 15 (2005) 4619
28. The relative efficacy of compound 17 was 86% of that of GW501516.
29. The X-ray structure of PPARδ complexed with GW2433 (PDB code 1GWX) was used as the target structure for docking. Protein preparation, receptor grid generation and ligand docking were performed using the software Glide 3.5. Compound 17 was docked into the ligand binding site of PPARδ. The extra precision mode of Glide was used to determine favorable binding poses, which allowed the ligand conformation to be flexibly explored while holding the protein as a rigid structure during docking. The predicted complex structure was then fully energy-minimized with both the protein and the ligand allowed to move using Macromodel 8.1 software. The conformation of 17 in the PPARδ ligand binding site was minimized by MM calculation based upon the OPLS-AA force field with each parameter set as follows; solvent: water, method: LBFGS, Max # Iterations: 10,000, Converge on: Gradient, Convergence Threshhold: 0.05.
30. Gampe Jr. R.T., Montana V.G., Lambert M.H., Miller A.B., Bledsoe R.K., Milburn M.V., Kliewer S.A., Willson T.M., and Xu H.E. Mol. Cell 5 (2000) 545